A recent position paper (from ESPGHAN) (I Hojsak et al. JPGN 2016; 62: 776-92) made me wonder how different people can look at the same data and come to opposite conclusions.
In short, this article systemically reviews intravenous lipid emulsions and the risk of hepatotoxicity. The review on the data is quite helpful. The authors conclude that short-term use of the various emulsions currently in use do not result in a significant difference in neonates, infants and children.
The authors acknowledge that the data for long-term use of these emulsions is limited. They state that “there is evidence indicating that just tailoring and adjusting PN in children on long-term PN could improve liver disease, meaning that the focus should not only be on the type of ILE.”
“Although the quality of data are lacking there is some evidence that the use of multicomponent fish oil-containing ILE may contribute to a decrease” in liver toxicity.
What I don’t understand: The authors recommend: “it appears prudent to use multicomponent FO [fish oil]-containing ILE (GR C)” and literally the next sentence: “The present evidence base is inadequate to determine the optimal strategy for intravenous lipid supply.”
My take: I think we need to gather the data before having official position paper recommendations.
Related blog posts:
- Medical Progress for Intestinal Failure Associated Liver …
- Fish Oil, IFALD, and Liver Fibrosis | gutsandgrowth
- Foil PNALD with FOLE? | gutsandgrowth
- PNAC, PNALD, and IFAC | gutsandgrowth
- IFfy outcome | gutsandgrowth
- Omega-3 Fatty Acids, Lipid Emulsions, and Hepatic Pathology
- Four advances for intestinal failure | gutsandgrowth